BNP/CALL/EVOTEC/22/0.1/20.12.24 Stock

Warrant

DE000PE00NG5

Real-time Boerse Frankfurt Warrants 03:20:45 2024-07-01 EDT
0.004 EUR 0.00% Intraday chart for BNP/CALL/EVOTEC/22/0.1/20.12.24
3 months-91.67%
6 months-98.97%
Date Price Change
24-07-01 0.004 0.00%
24-06-28 0.004 -20.00%
24-06-27 0.005 +25.00%
24-06-26 0.004 -20.00%
24-06-25 0.005 0.00%

Real-time Boerse Frankfurt Warrants

Last update July 01, 2024 at 03:20 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying EVOTEC SE
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PE00NG
ISINDE000PE00NG5
Date issued 2023-03-21
Strike 22
Maturity 2024-12-20 (173 Days)
Parity 10 : 1
Emission price 0.28
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.64
Lowest since issue 0.002
Delta0.12x
Omega 4.286
Premium143.6x
Gearing34.49x
Moneyness 0.4155
Difference Strike 12.9
Difference Strike %+58.64%
Spread 0.045
Spread %91.84%
Theoretical value 0.0265
Implied Volatility 86.64 %
Total Loss Probability 95.98 %
Intrinsic value 0.000000
Present value 0.0265
Break even 22.27 €
Theta-0x
Vega0x
Rho0x

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.975 EUR
Average target price
20.79 EUR
Spread / Average Target
+131.64%
Consensus